Pharma join together to achieve new standards in digital and patient innovation for clinical transformation

Reuters Events 17 - 19 May 2022, Virtual.
On May 17th , 500+ of pharma's clinical innovation will come together for the home of clinical collaboration, Reuters Events: Pharma Clinical 2022, to set new standards in digital and patient innovation for clinical transformation.

The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn't being done for patients, failing to develop co-created, data-driven, standardised and accountable trial design.

Senior leaders from Sanofi, Pfizer, Bayer, FDA, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Roche, Novartis and more are collaborating on May 17 th , with one mission in mind: it's time to develop a better system. "We must establish new industry-wide benchmarks, leverage digital technology, and ensure permanent cultural change toward patient- centric trials. If we don't act immediately, we risk losing patient trust." Said Usmaan Khan, Global Project Director and leader for Reuters Events: Pharma Clinical 2022.

The community is growing every day so don't miss out on the opportunity to be part of this movement- this event is free for pharma and biotech executives, patient advocates and patient associations! Secure your pass today here.

About Reuters Events: Pharma Clinical 2022, May 17-19th

Reuters Events: Pharma Clinical is proud to host a one-of-a-kind lineup, with more than 40 world-class and professional speakers. Among the speakers are:
  • Jijo James, CMO, Medical Devises, Johnson & Johnson
  • Lionel Bascles, SVP, Global Head of Clinical Sciences & Operations, Sanofi
  • Craig Lipset, Advisor and founder, Clinical Innovations Partners
  • Loredana Regep, VP Medical and Regulatory Affairs, Roche
  • Najat Khan, Chief Data Science Officer, Global Head, Janssen R&D Strategy and Operations, Johnson & Johnson
  • Dietmar Berger, CMO, Global Head of Development, Sanofi
  • Tracy Vanderslice, VP & Head, Pharma Global Clinical Operations, GSK
  • Venkat Sethuraman, SVP Global Biometrics and Data Science, Bristol-Myers Squibb

Click here to discover the full speaker line-up now!

Why should you attend?

On last year's event, Mo Ali, VP Digital Analytics and Performance said: "Clinical 2021 allows for open discussions around how we can do this, by sharing experiences and learnings, we expand on the art of the possible from what once several years ago may have been viewed as impossible"

Clinical 2022 builds on this with our insight-driven agenda co-created with industry leaders to guarantee you acquire practical knowledge that will help you succeed. With 40+ speakers, you'll access critical sessions related to:

  • Benchmark industry-wide clinical innovation: Align standards across stakeholders, establish benchmarks, maintain accountability, and set industry-wide goals to improve patient experience and trial performance
  • Co-creation or no creation: Create shared missions, education programmes, and centre digital advances around patients to create trial designs that work in the real world
  • Optimise your digital and data strategies for novel endpoints: Develop trial flexibility, design efficiency, and unique RWE endpoints through standardised and tested innovations
  • Data collaboration: Ensure smooth interoperable data transmissions across the company's digital innovation and health networks for streamlined trials
  • Evolve decentralised trials: Allow decentralised trials to thrive by providing ongoing trial breakthroughs that are backed by regulators and prioritise the patient.

Interested in sponsoring or speaking at Clinical 2022? Fill out the form here.

For further information and to register, please visit Pharma Clinical 2022

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Recurring brain tumor growth is halted with new dr…

When a non-metastatic brain tumor - a meningioma - recurs after surgery and radiation treatment, a patient is out of options. No drugs are approved for these aggressive t...

Pfizer to acquire Biohaven Pharmaceuticals

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) have entered into a definitive agreement under which Pfizer will acquire Biohaven, t...